<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/212FBA96-7037-4D15-818A-22ECC6A7E6A8"><gtr:id>212FBA96-7037-4D15-818A-22ECC6A7E6A8</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>Lingford-Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C67373B7-D390-4D49-BD31-1280BA65D1F5"><gtr:id>C67373B7-D390-4D49-BD31-1280BA65D1F5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Nutt</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77B5A46C-7B57-46DD-91A6-EEBC4DB00D0D"><gtr:id>77B5A46C-7B57-46DD-91A6-EEBC4DB00D0D</gtr:id><gtr:firstName>Federico</gtr:firstName><gtr:otherNames>Edoardo</gtr:otherNames><gtr:surname>Turkheimer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/80AA2433-C6E0-4428-9ED3-BC2C7DCB90A0"><gtr:id>80AA2433-C6E0-4428-9ED3-BC2C7DCB90A0</gtr:id><gtr:firstName>Bengt</gtr:firstName><gtr:surname>L?ngstr?m</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB544473-6BB4-495F-B7D1-D404EE8C059C"><gtr:id>FB544473-6BB4-495F-B7D1-D404EE8C059C</gtr:id><gtr:firstName>Laurence</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Reed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002226"><gtr:id>9152CC29-889B-4888-9077-E80CDB917B4D</gtr:id><gtr:title>Neurotransmitters in Opiate and Alcohol Addiction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1002226</gtr:grantReference><gtr:abstractText>Addiction is a widespread problem in our society and globally. This series of investigations continues our work in the study of 2 of the commonest and most harmful addictions, opiates (heroin) and alcohol. Many factors influence the entrance to addiction, its maintenance and the relapse to drugs in people who have abstained. We are studying in detail one of these factors, the brain mechanisms behind addiction, and in particular what brain chemicals (neurotransmitters) are involved. We have found that people with different addictions may have a shared deficit in the key neurotransmitter that calms the brain (GABA) which may explain why they have trouble controlling their desire to take drugs. Also we have evidence that the brain?s own pleasure system, the endorphins, may play a role in addiction. The current research program follows up these leads to see if they may also be important in an addiction that does not involve drugs ? gambling ? to see if they have a more general role in addiction. From these findings we have already identified potential avenues for development of new treatments and we hope that further discoveries we make will encourage companies to develop new research into treatments. 
We are a unique group in the UK because we have been using brain scanning (PET neuroimaging) techniques in addicts and in healthy volunteers to look at brain mechanisms for some years. Our group is comprised of doctors who treat addicts, specialists in PET and MRI imaging, and psychopharmacologists with expertise in drugs of addiction and brain receptors. We have been fortunate to interest many of the clients we meet in our day-to-day practice, who have volunteered in our studies and allowed us to scan their brains, and this interest continues.
We are experienced in and committed to publishing our results to the scientific community by presenting at conferences and writing in journals. We hold regular meetings with organisations helping addicts in their recovery. We communicate a lot with to the public through events such as science festivals and public science events, and through the media by taking part in radio and TV programmes about addiction.</gtr:abstractText><gtr:technicalSummary>This program of research tackles the brain mechanisms underpinning two of the most prevalent and costly addictions in the UK, those to opioids (heroin) and to alcohol. Using complementary techniques of brain imaging with PET tracers and challenge tests with neurotransmitter-targeted drugs we will build on the findings of our previous work to explore further the role of the dopaminergic system with two of its key modulators, GABA and opioid. PET studies of the dopaminergic system in addiction have had an immense influence on our understanding and we now have the tools to similarly comprehensively investigate GABA and opioid systems. To explore if significant findings are of general relevance to addiction rather than being a consequence of prior drug/alcohol use, key experiments will be made in the behavioural addiction of gambling. 

Specifically we shall explore the following theories: 

1. using the first alpha5 subtype-selective GABA-A tracer 11C-Ro154513 (we developed, validated and demonstrated lower levels in alcohol and heroin addicts in key areas involved in addiction eg nucleus accumbens), we shall explore if similar reductions are found in pathological gambling addiction. We shall test the hypothesis that GABA-ergic function is dysregulated in heroin and alcohol addiction by exploiting the fact that 11C-Ro15 4513 is sensitive to changing endogenous GABA levels and by using challenge tests and monitor subjective and objective (EEG, saccadic eye movements) outcomes with the GABA reuptake blocker, tiagabine and GABA-B agonist, baclofen. 
 
2. using the mu selective agonist PET tracer 11C-carfentanil to test the theory that increased endogenous opioids are involved in mediating pleasurable effects of alcohol and are evident in response to salient cues in alcohol, heroin addiction and pathological gambling. We shall test the hypothesis that there is reduced endogenous opioid reserve in alcoholism. We will test the theory that mu opiate receptors are implicated in impulsivity in these addicts. 

3. using the DRD2/3 selective dopamine PET tracer 11C-PHNO, with a selective DRD3 antagonist, we will determine whether the dopamine DRD3 receptor levels are increased in heroin addiction as well as in alcohol addiction.

Our results will help characterize the brain mechanisms of addiction and so further underpin the evidence base for its being, at least in part, a brain disorder. Our programme will lead to a better understanding of how current treatments work and will assist in the development of new ones.</gtr:technicalSummary><gtr:fund><gtr:end>2016-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1598517</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>channel 4 science program</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE1A9954-CACE-4241-84C8-E83F19F4A995</gtr:id><gtr:impact>first uk braim imaging study of mdma 
funded by channel 4

most downloaded programme ever for channel 4</gtr:impact><gtr:outcomeId>KrSug9ZScKy</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Disseminating information about the MARC scheme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C4D72F1F-2501-4E2D-B39F-AE02C0902731</gtr:id><gtr:impact>Presented MARC scheme, its aims and opportunities. Presented at RCPsych Addictions Faculty Meeting 2016 as well as other regional meetings alongside presentation of research outputs from other grants</gtr:impact><gtr:outcomeId>58c113634c56d7.46017246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.imperial.ac.uk/medicine/mrc-addiction-research-clinical-training/</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>29068973-4834-4C91-B7FB-0B8BA7A4774D</gtr:id><gtr:title>A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c125bf00e8b99982bcddb77b4bf18c4"><gtr:id>9c125bf00e8b99982bcddb77b4bf18c4</gtr:id><gtr:otherNames>Watson BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545a5b3a1f4c00.21983174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30BF056A-450F-460F-9C81-397103EDDFF4</gtr:id><gtr:title>A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced a5 benzodiazepine receptors in limbic regions.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdb2a9c9fc56464edeebc94d8161093c"><gtr:id>fdb2a9c9fc56464edeebc94d8161093c</gtr:id><gtr:otherNames>Lingford-Hughes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b397c24e5.32164184</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B077AFDF-5805-4DC7-8AD5-F2E88005A4C1</gtr:id><gtr:title>Single chemical entity legal highs: assessing the risk for long term harm.</gtr:title><gtr:parentPublicationTitle>Current drug abuse reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b28aea1060a096702c207916ff95848"><gtr:id>9b28aea1060a096702c207916ff95848</gtr:id><gtr:otherNames>McNabb CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-4737</gtr:issn><gtr:outcomeId>585d6373580307.41527346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B37FD0A-4D13-476E-AF88-797D3647253B</gtr:id><gtr:title>Optimising PET approaches to measuring 5-HT release in human brain.</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd88b8d24130045ac130004f202c5857"><gtr:id>dd88b8d24130045ac130004f202c5857</gtr:id><gtr:otherNames>Tyacke RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>5675e6daadfb2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81CE72AF-9813-4BC3-8502-9D91A0A5495E</gtr:id><gtr:title>The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a84a97df2a89df202c0c974f8cd7532"><gtr:id>4a84a97df2a89df202c0c974f8cd7532</gtr:id><gtr:otherNames>Mendez MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>545a5b3ba7c569.82935018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3D9D034-AEAB-42DD-BD51-A6BBE6DA985F</gtr:id><gtr:title>Substance abuse disorders.</gtr:title><gtr:parentPublicationTitle>Handbook of clinical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2970e905a18b09a6cfc4717bca033fb"><gtr:id>d2970e905a18b09a6cfc4717bca033fb</gtr:id><gtr:otherNames>Reid AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0072-9752</gtr:issn><gtr:outcomeId>545a5b3bcb32e3.75504476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69F63306-B972-4EE5-ACA4-B886A4FBBF4A</gtr:id><gtr:title>Alcohol-related brain damage: report from a Medical Council on Alcohol Symposium, June 2010.</gtr:title><gtr:parentPublicationTitle>Alcohol and alcoholism (Oxford, Oxfordshire)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20409ee7c596c92966cc315239093c4d"><gtr:id>20409ee7c596c92966cc315239093c4d</gtr:id><gtr:otherNames>Thomson AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0735-0414</gtr:issn><gtr:outcomeId>545a5b3b5e00b6.67451666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8863153-73F5-47CA-B230-FC2C7A18CE5E</gtr:id><gtr:title>Influence of different cellular environments on [(3)H]DASB radioligand binding.</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab6b183b25736a83c820747a14448aff"><gtr:id>ab6b183b25736a83c820747a14448aff</gtr:id><gtr:otherNames>Quelch DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>545a5b3c69d1e0.91810399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30A20728-E97F-4238-AC4E-B3581398579D</gtr:id><gtr:title>History of cigarette smoking is associated with higher limbic GABAA receptor availability.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>pm_13654_24_23247185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF6EA711-B69D-455E-AFB7-DE9AE1E91D50</gtr:id><gtr:title>Striatal dopamine D2/D3 receptor binding in pathological gambling is correlated with mood-related impulsivity</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd6b47e5a50a1922a22eb25838e6d775"><gtr:id>fd6b47e5a50a1922a22eb25838e6d775</gtr:id><gtr:otherNames>Clark L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>545a5b3c1dd8f1.38506014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6E3698C-D99E-4325-90BD-9226E814B926</gtr:id><gtr:title>Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4e5e248878a874673b0e17efd75d4d0"><gtr:id>e4e5e248878a874673b0e17efd75d4d0</gtr:id><gtr:otherNames>Green A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13654_24_23364815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87DDB371-8320-45E5-8047-E8670F940F54</gtr:id><gtr:title>Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive Attenuations.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2405be3c82991b503e7b1467e88160f"><gtr:id>b2405be3c82991b503e7b1467e88160f</gtr:id><gtr:otherNames>Herzig DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>545a5984e70782.71212165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>985165F4-C962-49D6-9A6E-4F5694BE52A6</gtr:id><gtr:title>Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e3a1452a9992adec71fb56290a99966"><gtr:id>8e3a1452a9992adec71fb56290a99966</gtr:id><gtr:otherNames>Korpi ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>585d60909b2bb7.74025938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B895C805-E329-4D67-B5A7-63DEAE168CCF</gtr:id><gtr:title>Neural substrates of cue reactivity and craving in gambling disorder.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/197b7115acea4160aacae718b9a4cf94"><gtr:id>197b7115acea4160aacae718b9a4cf94</gtr:id><gtr:otherNames>Limbrick-Oldfield EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>588b5a257ac0e3.76610334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ABE1B29-62EF-4930-9EBF-346D634085BE</gtr:id><gtr:title>Personalized risk assessment of drug-related harm is associated with health outcomes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f546d5e89334f49054d9708fcb01ac9"><gtr:id>1f546d5e89334f49054d9708fcb01ac9</gtr:id><gtr:otherNames>Jones AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545a5b3ed78e43.22702281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD80E84A-8BD9-40DF-BEFC-73FF434448FA</gtr:id><gtr:title>Substitution therapy for alcoholism: time for a reappraisal?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd4e071e44f4c239c5bf78523d317da8"><gtr:id>cd4e071e44f4c239c5bf78523d317da8</gtr:id><gtr:otherNames>Chick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13654_24_21742726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>255F57B6-0C52-41E5-9E2D-72642E87DA16</gtr:id><gtr:title>Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1306d16bedaa7bb38996e009e78c30b"><gtr:id>f1306d16bedaa7bb38996e009e78c30b</gtr:id><gtr:otherNames>Melichar JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>866CFDD1079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9F623C5-FB1C-4B12-8DDC-A3E397D5EDB3</gtr:id><gtr:title>Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET.</gtr:title><gtr:parentPublicationTitle>Addiction biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c125bf00e8b99982bcddb77b4bf18c4"><gtr:id>9c125bf00e8b99982bcddb77b4bf18c4</gtr:id><gtr:otherNames>Watson BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-6215</gtr:issn><gtr:outcomeId>pm_13654_24_23829344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E7CDDEA-6EBB-4298-8801-9EF52224F3DB</gtr:id><gtr:title>Neuropsychopharmacology across brain diseases.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>545a5b3cd85977.71413945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05AFC677-5577-4F9F-9B57-B89258866274</gtr:id><gtr:title>CNS drug development in Europe--past progress and future challenges.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>545a5b3e13b021.25002952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>246CFE4C-A1AC-4D5F-9BCB-2C63ECBDE708</gtr:id><gtr:title>Is socioeconomic status in early life associated with drug use? A systematic review of the evidence.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f1c89af17e4957c39625fff683d2a8e"><gtr:id>8f1c89af17e4957c39625fff683d2a8e</gtr:id><gtr:otherNames>Daniel JZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-5236</gtr:issn><gtr:outcomeId>GacJZc1MVxE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24E3BAE2-2A5E-40ED-B25E-B83E0538897F</gtr:id><gtr:title>Opioids and anxiety.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b38b282b1.10752523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEDCA8B9-D23A-4887-A5D1-28DDF3EFF14E</gtr:id><gtr:title>Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfaffda7f0c70f3f89bd89295b524d5d"><gtr:id>cfaffda7f0c70f3f89bd89295b524d5d</gtr:id><gtr:otherNames>Owen DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56bafb61d370d7.23967258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988D17D8-3DDC-440D-9ECF-6DA715916FB5</gtr:id><gtr:title>Dissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a204b8a3d47fba451af19560ec2abf6"><gtr:id>1a204b8a3d47fba451af19560ec2abf6</gtr:id><gtr:otherNames>Caprioli D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>doi_55f9859855b7143f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2E2592E-DC2D-45D1-9011-856AD3B8BDB0</gtr:id><gtr:title>Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9fddae568144e03169a9a3a1a94b8c8"><gtr:id>e9fddae568144e03169a9a3a1a94b8c8</gtr:id><gtr:otherNames>Argyropoulos SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56bafb6046fbc0.12996186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3F8FFB4-7A5A-47AD-8FF8-38DE08D87CDC</gtr:id><gtr:title>Anxiolytics.</gtr:title><gtr:parentPublicationTitle>Handbook of clinical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c5cb125f1285d8386985420643e6b3"><gtr:id>c4c5cb125f1285d8386985420643e6b3</gtr:id><gtr:otherNames>Sinclair LI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0072-9752</gtr:issn><gtr:outcomeId>585d648c361435.16203980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9C6DB01-8EB2-4AED-8D48-1C2F0C68DBE8</gtr:id><gtr:title>Effects of cannabis use on outcomes of psychotic disorders: systematic review.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f789e6d88055ac8e0b025813050e8aa"><gtr:id>4f789e6d88055ac8e0b025813050e8aa</gtr:id><gtr:otherNames>Zammit S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>MS9Ajt7wEPv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53DACFD3-252D-4E90-ADF6-A9D9E898DB35</gtr:id><gtr:title>Anne Lingford-Hughes: to get into addiction, just say yes.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25717321b2b67901393ba7e142718aba"><gtr:id>25717321b2b67901393ba7e142718aba</gtr:id><gtr:otherNames>Mitchell F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>58c11211ea89f3.11614764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DABB6BD-E85B-4857-8380-2D67EDD84D71</gtr:id><gtr:title>Characterisation of the contribution of the GABA-benzodiazepine a1 receptor subtype to [(11)C]Ro15-4513 PET images.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31f031541d02146a4189f199542c5a26"><gtr:id>31f031541d02146a4189f199542c5a26</gtr:id><gtr:otherNames>Myers JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_13654_24_22214903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>188DE24E-923E-4944-8EF7-B27DEBDF8746</gtr:id><gtr:title>Defining substance use disorders: do we really need more than heavy use?</gtr:title><gtr:parentPublicationTitle>Alcohol and alcoholism (Oxford, Oxfordshire)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aea93b7186aaee2b77119abccbf36e62"><gtr:id>aea93b7186aaee2b77119abccbf36e62</gtr:id><gtr:otherNames>Rehm J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0735-0414</gtr:issn><gtr:outcomeId>545a5b3e677fb9.07857547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B9545C3-86C1-44C2-85F8-EB188850542F</gtr:id><gtr:title>Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline2 binding site.</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd88b8d24130045ac130004f202c5857"><gtr:id>dd88b8d24130045ac130004f202c5857</gtr:id><gtr:otherNames>Tyacke RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>545a5b3b384246.92680732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2CAFCAF-B8E3-4DC0-BE5E-98E71AE974F6</gtr:id><gtr:title>History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3a71b6b3.24607667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC680291-610C-45CC-A38C-5CD1E5CA4179</gtr:id><gtr:title>Amphetamine, past and present--a pharmacological and clinical perspective.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95c9cd35cab2440c9c51790057ce75e7"><gtr:id>95c9cd35cab2440c9c51790057ce75e7</gtr:id><gtr:otherNames>Heal DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3d823ca2.72711622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2946A737-7231-41C7-BA2A-47F712379152</gtr:id><gtr:title>Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: a study in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c9136b2450fe695b3b016b3d6b265"><gtr:id>334c9136b2450fe695b3b016b3d6b265</gtr:id><gtr:otherNames>Nutt D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>545a5984be8536.02675520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22BBB2F6-D5BC-46AD-9C68-4EA59B32B44B</gtr:id><gtr:title>Measurement of GABA using J-difference edited 1H-MRS following modulation of synaptic GABA concentration with tiagabine.</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31f031541d02146a4189f199542c5a26"><gtr:id>31f031541d02146a4189f199542c5a26</gtr:id><gtr:otherNames>Myers JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>545a5b3fee5694.02710616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B9041E-E9D0-4882-A56E-3BF64E917965</gtr:id><gtr:title>The size, burden and cost of disorders of the brain in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a2b61f5c673587c0222d91973574a86"><gtr:id>7a2b61f5c673587c0222d91973574a86</gtr:id><gtr:otherNames>Fineberg NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3e3ceae8.95358573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>634E0CA8-9638-4C58-8297-DE7C1480957A</gtr:id><gtr:title>Pharmacological cognitive enhancement in healthy people: potential and concerns.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/893b8dfbe3e54cdf4616fd5fb0c55a09"><gtr:id>893b8dfbe3e54cdf4616fd5fb0c55a09</gtr:id><gtr:otherNames>Hyman S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>56bafb623226b6.47921279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DACFB6AF-5EBE-4281-B363-51308CA259AB</gtr:id><gtr:title>Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/980cfcfb377e376208b8102e1ccf1bb0"><gtr:id>980cfcfb377e376208b8102e1ccf1bb0</gtr:id><gtr:otherNames>Kalk NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>545a5b3dce9112.59153227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989BD1BC-936C-4BF7-96A9-F0CFB4590222</gtr:id><gtr:title>The clinical pharmacology of acamprosate.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/980cfcfb377e376208b8102e1ccf1bb0"><gtr:id>980cfcfb377e376208b8102e1ccf1bb0</gtr:id><gtr:otherNames>Kalk NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>545a5b3d3ab671.62390778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B21B2D7-2512-4F05-96A8-1A45BA7F671A</gtr:id><gtr:title>Doing it by numbers: a simple approach to reducing the harms of alcohol.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3f7c1db2.83953417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DED799E-D943-4D9F-BEBD-A79E84B0DC6C</gtr:id><gtr:title>Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of analytical toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b66976fdb76eebd8474d090fc9261d44"><gtr:id>b66976fdb76eebd8474d090fc9261d44</gtr:id><gtr:otherNames>Nahar LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0146-4760</gtr:issn><gtr:outcomeId>585d5d8ad62376.71265281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>002D5C1F-D9FE-4A9C-A86C-DC5036B2B152</gtr:id><gtr:title>Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3b113af4.76181838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9D4E1C9-7813-4CF6-953E-E9BCD628B4B1</gtr:id><gtr:title>Low serotonergic tone and elevated risk for substance misuse.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c9136b2450fe695b3b016b3d6b265"><gtr:id>334c9136b2450fe695b3b016b3d6b265</gtr:id><gtr:otherNames>Nutt D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>56bafb6483a218.56093798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EDDE84C-1265-4DEE-B17F-EB9A2DCD672D</gtr:id><gtr:title>New victims of current drug laws.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>pm_13654_24_24149187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ABD1167-3742-4ADF-B497-73CE23DCC834</gtr:id><gtr:title>Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56bb024bd42201.59683210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>548482DB-C4E8-471A-9F86-DBE1A0EB385E</gtr:id><gtr:title>In vivo imaging of cerebral dopamine D3 receptors in alcoholism.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d531b533ab302f5e81ef309c98b582c4"><gtr:id>d531b533ab302f5e81ef309c98b582c4</gtr:id><gtr:otherNames>Erritzoe D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>545a5b3fa08a81.09799443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C63C01FB-CA81-4DA5-8C0D-A0EE972A9F4E</gtr:id><gtr:title>Imaging endogenous opioid peptide release with [11C]carfentanil and [3H]diprenorphine: influence of agonist-induced internalization.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab6b183b25736a83c820747a14448aff"><gtr:id>ab6b183b25736a83c820747a14448aff</gtr:id><gtr:otherNames>Quelch DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>545a5b408b1414.55435512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95B194DE-A20D-4546-85C0-5E992BD294DE</gtr:id><gtr:title>Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health.</gtr:title><gtr:parentPublicationTitle>Addiction biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d238b9b85608c14e58b1d6eb6e0144e"><gtr:id>5d238b9b85608c14e58b1d6eb6e0144e</gtr:id><gtr:otherNames>Badiani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1355-6215</gtr:issn><gtr:outcomeId>5a578bf4d318a0.11828173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>316228B1-82A3-4895-865A-4694F6F215E9</gtr:id><gtr:title>Endogenous opioid release in the human brain reward system induced by acute amphetamine administration.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>545a5b3b81eef6.99936018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3322A124-1B85-406A-8AC2-43314CACF6C6</gtr:id><gtr:title>Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>gGVYt9xXzDn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3A6720B-C555-42DF-9F6D-1D79AE6DFCA0</gtr:id><gtr:title>The influence of different cellular environments on PET radioligand binding: an application to D2/3-dopamine receptor imaging.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab6b183b25736a83c820747a14448aff"><gtr:id>ab6b183b25736a83c820747a14448aff</gtr:id><gtr:otherNames>Quelch DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>545a5b406a2bc5.95987015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DB67DF0-4A20-46F9-847F-2EA45745E696</gtr:id><gtr:title>Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac842786439e217b7106b717ca6d425c"><gtr:id>ac842786439e217b7106b717ca6d425c</gtr:id><gtr:otherNames>Williams TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>b61rkn9DwBU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B27307DB-7D20-46E8-8122-22E2C93EF55C</gtr:id><gtr:title>Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.</gtr:title><gtr:parentPublicationTitle>European addiction research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09d883d26f08f9fc31846dad9ae0cd53"><gtr:id>09d883d26f08f9fc31846dad9ae0cd53</gtr:id><gtr:otherNames>Aubin HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1022-6877</gtr:issn><gtr:outcomeId>5675e1a805c05</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8373F262-105C-4C3C-8EEC-AC6C60911D94</gtr:id><gtr:title>The dopamine theory of addiction: 40 years of highs and lows.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>5675e264d56db</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E4735CF-65A7-4BA5-9591-418D31703A23</gtr:id><gtr:title>Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/173372c773cb74de920a320f6973eae7"><gtr:id>173372c773cb74de920a320f6973eae7</gtr:id><gtr:otherNames>Muthukumaraswamy SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>545a5b3d5f37b0.01319651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA6AD182-DECA-432D-B9DA-FBD2D54DF76D</gtr:id><gtr:title>BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c8164a415046134aebb488fa1f0b3c1"><gtr:id>3c8164a415046134aebb488fa1f0b3c1</gtr:id><gtr:otherNames>Lingford-Hughes AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3bef06a8.42462994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>326222D9-57EF-487D-A2C1-A3C399C783D6</gtr:id><gtr:title>GABAB receptors in addiction and its treatment.</gtr:title><gtr:parentPublicationTitle>Advances in pharmacology (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd88b8d24130045ac130004f202c5857"><gtr:id>dd88b8d24130045ac130004f202c5857</gtr:id><gtr:otherNames>Tyacke RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1054-3589</gtr:issn><gtr:outcomeId>WZ7ivdSMevX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32CA760F-2E95-4850-A1BD-BB363E8716D8</gtr:id><gtr:title>Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>545a5b3c8e82b0.57619466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C953D5F-2464-4873-AA41-73707FF785A5</gtr:id><gtr:title>The effects of elevated endogenous GABA levels on movement-related network oscillations.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/173372c773cb74de920a320f6973eae7"><gtr:id>173372c773cb74de920a320f6973eae7</gtr:id><gtr:otherNames>Muthukumaraswamy SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>545a5b3cb18060.02757262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2F648BB-8340-43FC-AAE2-E8F735B8275A</gtr:id><gtr:title>Antidepressant treatment response: 'I want it all, and I want it now!'?.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b80f2919524875f448f7fcf1477b54"><gtr:id>a4b80f2919524875f448f7fcf1477b54</gtr:id><gtr:otherNames>Malhi GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>585d620ce864e9.30099885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B4813EC-8CCE-4F21-B765-1DEA98D44A5D</gtr:id><gtr:title>Let not the best be the enemy of the good.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c9136b2450fe695b3b016b3d6b265"><gtr:id>334c9136b2450fe695b3b016b3d6b265</gtr:id><gtr:otherNames>Nutt D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>56bafb64c88610.75434669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D4D924D-988A-4978-A668-4456856BCB73</gtr:id><gtr:title>Influence of agonist induced internalization on [3H]Ro15-4513 binding-an application to imaging fluctuations in endogenous GABA with positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a904b8999280c6c344895077ff4e55a8"><gtr:id>a904b8999280c6c344895077ff4e55a8</gtr:id><gtr:otherNames>Quelch D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>545a5b40b52504.91711347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B249EA0-8455-4D7C-ABC9-C4C45E0EC3E3</gtr:id><gtr:title>Generic legislation of new psychoactive drugs.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c51f27009ba3cc9c2d1c3f0c7e072973"><gtr:id>c51f27009ba3cc9c2d1c3f0c7e072973</gtr:id><gtr:otherNames>van Amsterdam J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56bafb61a1b007.88591726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BAD900C-BD0D-46A9-B5E5-4DDCEF6EFCF6</gtr:id><gtr:title>Ketamine--the real perspective.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d17a40065c79ceb4fda6c41bbac48e5"><gtr:id>3d17a40065c79ceb4fda6c41bbac48e5</gtr:id><gtr:otherNames>Taylor P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>585d5a65ddcd99.70414540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A46AA682-EB62-4BFA-BBB7-79F695CA38CF</gtr:id><gtr:title>Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4013d24911704de9f2cfb492695bc85"><gtr:id>b4013d24911704de9f2cfb492695bc85</gtr:id><gtr:otherNames>Mick I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>585d69eb721a30.34135615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8118ED9D-3730-4684-B19F-584D3D0697CA</gtr:id><gtr:title>Addiction: lifestyle choice or medical diagnosis?</gtr:title><gtr:parentPublicationTitle>Journal of evaluation in clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c9136b2450fe695b3b016b3d6b265"><gtr:id>334c9136b2450fe695b3b016b3d6b265</gtr:id><gtr:otherNames>Nutt D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1356-1294</gtr:issn><gtr:outcomeId>56bafb615f6ea9.24768149</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF5700D1-6E23-45F0-B7E9-1736B6558642</gtr:id><gtr:title>Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc1d7980839e06d5381e25db1ccd96b8"><gtr:id>cc1d7980839e06d5381e25db1ccd96b8</gtr:id><gtr:otherNames>Weissenborn R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3a961204.70344847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D1A679D-968C-41D1-A4EC-EEF4FBA76ED0</gtr:id><gtr:title>GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83edf587aea84eb36820ccf9e78701e1"><gtr:id>83edf587aea84eb36820ccf9e78701e1</gtr:id><gtr:otherNames>Papadopoulos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>585d5763147cb7.36021736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39314703-90D7-42C8-83ED-E2DAF2519B44</gtr:id><gtr:title>5-HT radioligands for human brain imaging with PET and SPECT.</gtr:title><gtr:parentPublicationTitle>Medicinal research reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdcfdb2a611d9920955e1839272fbc81"><gtr:id>cdcfdb2a611d9920955e1839272fbc81</gtr:id><gtr:otherNames>Paterson LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0198-6325</gtr:issn><gtr:outcomeId>545a5b3a42f2b8.01915205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18961BEE-38F7-471D-9E77-C785FBF2795B</gtr:id><gtr:title>Effects of Schedule I drug laws on neuroscience research and treatment innovation.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>pm_13654_24_23756634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADBD9C26-5820-43BF-AB34-F1F01C3D395C</gtr:id><gtr:title>Drug harms in the UK: a multicriteria decision analysis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>QH9cw3qd238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9DBF925-6292-4755-84CE-5546B492E96C</gtr:id><gtr:title>Does human presynaptic striatal dopamine function predict social conformity?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3f360634.47923557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A376C63-28B3-480C-9A7B-F001791DE828</gtr:id><gtr:title>Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdb2a9c9fc56464edeebc94d8161093c"><gtr:id>fdb2a9c9fc56464edeebc94d8161093c</gtr:id><gtr:otherNames>Lingford-Hughes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>585d59f7d8aba3.87216884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CC21A30-E468-4313-9F02-D5B2392DB8F8</gtr:id><gtr:title>No psychiatry without psychopharmacology.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05e91aca2dd795fe44436811684414dd"><gtr:id>05e91aca2dd795fe44436811684414dd</gtr:id><gtr:otherNames>Harrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>585d620ad60ee3.14312976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E3195CF-38E3-4FEB-908C-76255F91659F</gtr:id><gtr:title>The role of the opioid system in alcohol dependence.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13654_24_24048097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A646C115-A5D0-4AA0-8E0B-19C7411FA2D7</gtr:id><gtr:title>Single Chemical Entity Legal Highs: Assessing the Risk for Long Term Harm</gtr:title><gtr:parentPublicationTitle>Current Drug Abuse Reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faae6c2bc1d514b0d870b5ff6cd9a476"><gtr:id>faae6c2bc1d514b0d870b5ff6cd9a476</gtr:id><gtr:otherNames>B. McNabb C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5a6f067eb65416.36094186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7624DC8B-50C2-40DF-8EF5-1934E31B5571</gtr:id><gtr:title>Amphetamine induced endogenous opioid release in the human brain detected with [&amp;sup1;&amp;sup1;C]carfentanil PET: replication in an independent cohort.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4013d24911704de9f2cfb492695bc85"><gtr:id>b4013d24911704de9f2cfb492695bc85</gtr:id><gtr:otherNames>Mick I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>545a5b401fbd74.28858925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81905C51-12D5-4462-999E-683E2045B88A</gtr:id><gtr:title>Benzodiazepines: risks and benefits. A reconsideration.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e6466fa42b7c337cb5383a05be3dad9"><gtr:id>1e6466fa42b7c337cb5383a05be3dad9</gtr:id><gtr:otherNames>Baldwin DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b3e8def98.47865553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88B9238B-6735-4820-9BF0-E1FD7630C848</gtr:id><gtr:title>Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.</gtr:title><gtr:parentPublicationTitle>Addiction biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4013d24911704de9f2cfb492695bc85"><gtr:id>b4013d24911704de9f2cfb492695bc85</gtr:id><gtr:otherNames>Mick I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1355-6215</gtr:issn><gtr:outcomeId>585d601e7662d6.03826955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFF88C3D-C79C-4765-A27B-E00AB5EC7C00</gtr:id><gtr:title>Does alcohol increase the risk of overdose death: the need for a translational approach.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a21002105f03f66eed67137e868864"><gtr:id>b6a21002105f03f66eed67137e868864</gtr:id><gtr:otherNames>Hickman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>rxm46qytKMk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>030E48D1-3A99-4695-9F28-25F6E0FB56C9</gtr:id><gtr:title>GABA system dysfunction in autism and related disorders: from synapse to symptoms.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e3ffe3d293392c3467ddaba0a315b7d"><gtr:id>2e3ffe3d293392c3467ddaba0a315b7d</gtr:id><gtr:otherNames>Coghlan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>545a5b3c40dc74.85532667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF18D20D-1DA7-40E5-A22D-F0F4339F7442</gtr:id><gtr:title>Acute increases in synaptic GABA detectable in the living human brain: a [&amp;sup1;&amp;sup1;C]Ro15-4513 PET study.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>545a5b40479715.03464404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A354F9F-4AAB-42C6-A289-4F98B08516E0</gtr:id><gtr:title>Addiction: the clinical interface.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c9136b2450fe695b3b016b3d6b265"><gtr:id>334c9136b2450fe695b3b016b3d6b265</gtr:id><gtr:otherNames>Nutt D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>US7TbzYm1iM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC961CDB-1E28-4B18-8950-01886AF7B726</gtr:id><gtr:title>Innovative solutions to novel drug development in mental health.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbdbdaefcee4a2c0bf4f86c1b00061d7"><gtr:id>bbdbdaefcee4a2c0bf4f86c1b00061d7</gtr:id><gtr:otherNames>Insel TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>545a5b3da97a94.94178153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17431CB4-C55C-469A-8259-E2C779B5F2C4</gtr:id><gtr:title>Brain dopamine response in human opioid addiction.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45e9f0f6abb0711e7ad24db09196af60"><gtr:id>45e9f0f6abb0711e7ad24db09196af60</gtr:id><gtr:otherNames>Daglish MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>Sh2YUMxn2ZS</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002226</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>